Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 14/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 3/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953156 | 0.78 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL5677771 | 0.78 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL19570332 | 0.78 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL7713988 | 0.75 | MAP2K4 (0.49) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL8206970 | 0.74 | MAP2K4 (0.47) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL30982343 | 0.73 | MAP2K4 (0.46) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL5635008 | 0.73 | MAP2K4 (0.46) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL14979221 | 0.73 | MAP2K4 (0.54) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL1041713 | 0.73 | MAP2K4 (0.49) | MAP2K4MAPK1MAPK6ITKMAP2K7 | |
| SCHEMBL16365538 | 0.71 | FADS1 (0.42) | HTR2AGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | MAP2K4 3379/4885MAPK1 1150/4885MAPK6 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.